09.12.2009 • Topics

Lonza to Build Cell Therapy Facility in Singapor

Swiss drugs industry supplier Lonza Group said it was building a new facility in Singapore to expand its cell therapy business. Lonza said that the total investment for the first phase would be approximately 30 million Swiss francs ($27.03 million). Construction is due to begin in early 2010 and the facility is expected to be operational by mid-2011, it added. "The facility will operate with cutting-edge technologies and a skilled labor force, allowing it to readily meet the needs of a broad range of customers and address the growing global demand for Cell Therapies," said Lonza CEO Stefan Borgas in a statement.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.